


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT COMPLETION OF THE FIRST SUBJECT DOSING IN PHASE II CLINICAL TRIAL OF EDP167

This announcement is made by Edding Genor Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that its innovative small nucleic acid drug, EDP167, has successfully completed the first subject dosing in its Phase II clinical trial.

Phase II clinical trial of EDP167 is a multicenter, dose-finding and open-label trial in adult patients with Homozygous Familial Hypercholesterolemia (“**HoFH**”). The trial aims to evaluate the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (“**LDL-C**”) levels relative to baseline after 24 weeks of first dosing. Assessment of the primary endpoint is expected to be completed in the fourth quarter of 2026.

ABOUT EDP167

EDP167 is an innovative siRNA therapeutic designed for the treatment of dyslipidemia, developed in line with one of the Company’s strategic focuses on cardiovascular diseases. The drug targets hepatic angiotensin-like protein 3 (“**ANGPTL3**”)—a key regulator secreted by the liver that simultaneously inhibits lipoprotein lipase and endothelial lipase, thereby modulating the metabolism of multiple atherogenic lipoproteins. Genetic studies confirm that individuals with loss-of-function mutations in ANGPTL3 have a significantly reduced risk of atherosclerotic cardiovascular disease.

Through precise and sustained silencing of hepatic ANGPTL3 expression, EDP167 achieves a dual potent reduction in LDL-C and triglyceride (“**TG**”) levels. Importantly, its mechanism of action is independent of the LDL receptor (“**LDLR**”) pathway, thereby overcoming the limitations of conventional lipid-lowering agents, including statins and PCSK9 inhibitors, which rely on LDLR function. This unique feature of EDP167 provides an important innovative treatment option for patients with dyslipidemia, especially those with HoFH or mixed dyslipidemia, and offers broad clinical application prospects.

Prior to initiating Phase II trials in patients with HoFH, the Company completed a randomized, double-blind, placebo-controlled, single ascending dose Phase I study in healthy subjects and individuals with mild dyslipidemia. This study evaluated the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of EDP167 across multiple dose levels. Results demonstrated that EDP167 exhibited favorable safety and tolerability profile. The data will be disclosed in the upcoming medical conference in 2026.

ABOUT THE COMPANY

The Company is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through acquisition of branded drug assets from multinational pharmaceutical companies (“MNC”) and licensing in development and commercialisation rights of innovative patented drugs from global biopharmaceutical companies, the Company has established a competitive portfolio of originator-branded drugs and innovative drugs. The Company has successfully brought multiple innovative drugs to market in China, reflecting its strong clinical development and management capabilities. Moreover, the Company has demonstrated high-quality manufacturing, supply chain management, technology transfer and quality control systems through operating the production facilities and management systems transferred from MNCs in its historical asset acquisitions.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 9 February 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Ms. Zhai Jing as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.